News & Views

  • Novel Approach Against Genetic Forms of Schizophrenia
    Professor George Baillie

Novel Approach Against Genetic Forms of Schizophrenia

Aug 22 2017 Read 1157 Times

A study led by the University of Glasgow has made a breakthrough in developing a possible future treatment for people with a hereditary form of schizophrenia and related psychiatric conditions. According to the report, current studies have shown that people in this group are deficient in the brain protein DISC1, an important multi-function ‘scaffolding’ protein vital to key brain functions.

The Glasgow research, led by George Baillie, Professor of Molecular Pharmacology at the Institute of Cardiovascular and Medical Science, has crucially identified the protein, FBXW7, which tags the DISC1 protein for destruction. They discovered that by disrupting the interaction between these two proteins with an inhibitory peptide, DISC1 deficiencies could be counteracted.

Professor Baillie said: “My colleagues and I decided to look specifically at the DISC1 protein. Our idea was simple: what would happen if we could simply raise the concentration of DISC1 in patients’ brains? We looked at the turnover of DISC1 in the brain and found it was rapidly made and then degraded by brain cells. We thought, if we can stop the natural destruction of DISC1, people with low levels would see it naturally increase. Using our peptide, we can now restore DISC1 concentrations in psychiatric patient derived brain cells back to the levels of control subjects.”

Schizophrenia affects around 1 in 100 people over the course of their life. It is present in twice as many people as Alzheimer’s Disease and five times as many people as Multiple Sclerosis, with an estimated cost to the economy of £6.7 billion each year.

Professor Baillie added: “Many patients respond inadequately or adversely to current psychiatric medications, so the development of new drugs to treat mental illness is needed, but unfortunately no substantial innovations in drug treatments for these debilitating disorders have emerged in the last 60 years. We are hopeful that our peptide can be a stepping stone toward a novel therapeutic in the future to counteract this unmet need”

“As positive as our discovery is, we have some way to go between laboratory findings and the clinical application, but we are hopeful that our research is the first step on a journey towards a potential new drug treatment option for a range of psychiatric illnesses.”

The paper, ‘FBXW7 regulates DISC1 stability via the ubiquitin-proteosome system’ is published in Molecular Psychiatry.

Reader comments

Do you like or dislike what you have read? Why not post a comment to tell others / the manufacturer and our Editor what you think. To leave comments please complete the form below. Providing the content is approved, your comment will be on screen in less than 24 hours. Leaving comments on product information and articles can assist with future editorial and article content. Post questions, thoughts or simply whether you like the content.

Post a Comment

Digital Edition

Lab Asia April 2019

April 2019

In This Edition Articles - Mobile Affinity Sorbent Chromatography Of Proteins - Integration of MS and UV Data for Peak Tracking in HPLC Method Development - VMXm takes its First Users 'wher...

View all digital editions


Analitika Expo 2019

Apr 23 2019 Moscow, Russia


Apr 30 2019 Chicago, IL, USA

Making Pharmaceuticals Exhibition & Conference 2019

Apr 30 2019 Ricoh Arena, Coventry, UK

AOCS Annual Meeting & Expo

May 05 2019 St. Louis, MO, USA

ISCC & GCxGC 2019

May 13 2019 Fort Worth, Tx, USA

View all events